COMP <GO>
PLUR vs JSPR // EV/EBITDA & P/E VALUATION
Pluri Inc. (NASDAQ) VS. Jasper Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: PLUR 2
— JSPR 1
■ METRIC PARITY
LAST: $1.20 (-2.44%) • MKT CAP: $16.1M
valuation
—
LAST: $0.53 (-1.26%) • MKT CAP: $17.7M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PLUR VS. JSPR)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PLUR | JSPR | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 49.00% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 180.00% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 2/9 | +1.00 | PLUR | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 61.7 | 44.3 | +17.32 | PLUR | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $16.1M | $17.7M | -$1.6M | JSPR | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PLUR REV | JSPR REV | PLUR GROSS % | JSPR GROSS % | PLUR FCF | JSPR FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.3M | $0 | 49.0% | — | -$19.8M | -$77.2M |
| FY 2024 | $326.0K | $0 | 98.0% | — | -$18.3M | -$62.6M |
| FY 2023 | $287.0K | $0 | — | — | -$22.9M | -$52.1M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PLUR // BETA —
JSPR // BETA —